Tweet
I just noted that in figure 3 future studies are mentioned but I do not know if in their lab:
Figure 3. Pan-coronavirus drug discovery.
Currently, the state of pan-coronavirus drug discovery is not structured to provide adequate pre-clinical therapeutics to combat emerging CoV pathogens. A diverse array of coronaviruses is
needed that includes epidemic isolates of SARS-CoV and MERS-CoV, zoonotic viruses isolated from intermediate reservoir hosts, pre-emergent CoVs from bats, and clinical isolates of mildly
pathogenic HCoVs. In vitro testing in compatible cell lines uses high throughput screening to identify novel targets that mitigate replication of coronaviruses. Targets identified by in vitro
methods can be confirmed using human airway epithelial cultures. Based on these results, lead targets will be tested in small animal models and nonhuman primate models of highly
pathogenic coronavirus infections that recapitulate signs of human SARS or MERS patients. Our analysis identified several key weaknesses in both in vitro and in vivo models of highlypathogenic coronavirus virus infection impeding the identification of pan-coronavirus antiviral drugs.
I am not accusing them. I would like only that all the possibilities can be considered and tested, not only in China.
Figure 3. Pan-coronavirus drug discovery.
Currently, the state of pan-coronavirus drug discovery is not structured to provide adequate pre-clinical therapeutics to combat emerging CoV pathogens. A diverse array of coronaviruses is
needed that includes epidemic isolates of SARS-CoV and MERS-CoV, zoonotic viruses isolated from intermediate reservoir hosts, pre-emergent CoVs from bats, and clinical isolates of mildly
pathogenic HCoVs. In vitro testing in compatible cell lines uses high throughput screening to identify novel targets that mitigate replication of coronaviruses. Targets identified by in vitro
methods can be confirmed using human airway epithelial cultures. Based on these results, lead targets will be tested in small animal models and nonhuman primate models of highly
pathogenic coronavirus infections that recapitulate signs of human SARS or MERS patients. Our analysis identified several key weaknesses in both in vitro and in vivo models of highlypathogenic coronavirus virus infection impeding the identification of pan-coronavirus antiviral drugs.
I am not accusing them. I would like only that all the possibilities can be considered and tested, not only in China.
Comment